Altimmune's CEO recently purchased 15,000 shares at $2.95 each, showing strong leadership confidence in the company's future. The biopharmaceutical firm reported a better-than-expected Q2 loss of $0.12 per share and holds $519 million in cash, securing funding through 2029. Increased R&D spending supports the Phase III PERFORMA trial for its MASH treatment, pemvidutide, alongside positive Phase II results for alcohol use disorder. These developments highlight Altimmune's promising pipeline and financial stability as it advances toward regulatory approval.
Unigold Inc. announced an updated mineral resource estimate for its Candelones Project in the Dominican Republic, reporting Measured and Indicated resources of 69.1 million tonnes averaging 1.03 g/t gold, containing 2.29 million ounces of gold, plus ...
Acurx Pharmaceuticals announced its Q2 2026 financial results, reporting a net loss of $2.3 million and ending the quarter with $10.7 million in cash. The company progressed its lead antibiotic candidate, ibezapolstat, preparing for Phase 3 trials ta...
Five US-listed Dividend Kings—Johnson & Johnson, Procter & Gamble, Coca-Cola, Colgate-Palmolive, and Lowe's—have announced dividend increases and reported earnings reflecting resilience amid economic challenges like tariffs and currency swings. Johns...
Evogene Ltd., a computational chemistry company, announced that its Chairman Nir Nimrodi will speak during the quarterly earnings call on August 18, 2026. He will discuss the current situation involving dissident shareholders and the potential impact...
Bank Leumi, Israel's largest bank, has partnered with Galaxy Digital to provide secure, regulated digital asset trading services to its customers. Starting early 2027, customers can trade Bitcoin, Ether, and Solana through the Leumi Trade app using G...
